Jatenzo's Legal Issues

Quote

































This decision was bad for Clarus. One of their patents was cancelled, which was affirmed here on appeal. Then there is the patent infringement lawsuit by Lipocine which may allow them to force Jatenzo off the market if they win. Trial is early next year. A recent Markman hearing went largely in favor of Lipocine. So if Clarus is smart they will settle now and pay a large royalty to Lipocine. Things are not going so well for Clarus.
 








anonymous said:
This decision was bad for Clarus. One of their patents was cancelled, which was affirmed here on appeal. Then there is the patent infringement lawsuit by Lipocine which may allow them to force Jatenzo off the market if they win. Trial is early next year. A recent Markman hearing went largely in favor of Lipocine. So if Clarus is smart they will settle now and pay a large royalty to Lipocine. Things are not going so well for Clarus.
Click to expand...

That's laughable. Last I checked, Lipocine was working on their 3rd CRL and didn't have a marketable product. Clarus should let the courts decide since they have money to launch and pay their lawyers. Lipocine on the other hand had to delay trial to 2021 because they are broke and can't raise money without an approved product. Lipocine should be approaching Clarus for a lifeline acquisition, not for a royalty.
 








anonymous said:
That's laughable. Last I checked, Lipocine was working on their 3rd CRL and didn't have a marketable product. Clarus should let the courts decide since they have money to launch and pay their lawyers. Lipocine on the other hand had to delay trial to 2021 because they are broke and can't raise money without an approved product. Lipocine should be approaching Clarus for a lifeline acquisition, not for a royalty.
Click to expand...

My thoughts exactly! Lipocine is grasping at straws here.
 
























It seems that Clarus Therapeutics as a privare company currently would have issues if they attempt to go public. This will be on hold until the patent battle with Lipocine is settled. It looks like Clarus is losing at this point. Is this a goal for Clarus? Going public?
 








anonymous said:
It seems that Clarus Therapeutics as a privare company currently would have issues if they attempt to go public. This will be on hold until the patent battle with Lipocine is settled. It looks like Clarus is losing at this point. Is this a goal for Clarus? Going public?
Click to expand...

l hope this is not the extent of your research. Amateur.
 
















anonymous said:
It seems that Clarus Therapeutics as a privare company currently would have issues if they attempt to go public. This will be on hold until the patent battle with Lipocine is settled. It looks like Clarus is losing at this point. Is this a goal for Clarus? Going public?
Click to expand...

Lipocine is definitely "winning". Zero approved products, legal bills, a costly clinical trial, they raise expensive money by diluting investors, plus they face delisting from the Nasdaq.
 








anonymous said:
That's laughable. Last I checked, Lipocine was working on their 3rd CRL and didn't have a marketable product. Clarus should let the courts decide since they have money to launch and pay their lawyers. Lipocine on the other hand had to delay trial to 2021 because they are broke and can't raise money without an approved product. Lipocine should be approaching Clarus for a lifeline acquisition, not for a royalty.
Click to expand...
Well, it doesn't really matter if they have a product or not. If Clarus is found to infringe on Lipocine's patents they will have to pay some form of compensation, most likely in the form of significant royalties. If, by then, Lipocine happens to have an approved product, it may allow them to ask the courts to force Clarus off the market. I am not sure how Clarus' new debt holders will view a significant court loss with the ensuing negative financial consequences for the company.
 








anonymous said:
Well, it doesn't really matter if they have a product or not. If Clarus is found to infringe on Lipocine's patents they will have to pay some form of compensation, most likely in the form of significant royalties. If, by then, Lipocine happens to have an approved product, it may allow them to ask the courts to force Clarus off the market. I am not sure how Clarus' new debt holders will view a significant court loss with the ensuing negative financial consequences for the company.
Click to expand...

You are correct. In fact it may be ironic that Clarus will support significantly Lipocine when the legal outcome rules in favor of Tlandro.
 








































Top Bottom
Back
Quote